Hepatitis B is potentially a life-threatening liver infection caused by the Hepatitis B Virus (HBV). It is a major global health problem and it can be an acute infection or a chronic infection. Chronic HBV infection is a leading cause of chronic hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
Hepatitis B virus (HBV) is a blood-borne and sexually transmitted virus that is acquired by percutaneous and mucosal exposure to blood or other body fluids of an infected person. Clinical manifestations of hepatitis from different origins may be quite similar.
In the Global Burden of Disease Study, 2010, HBV Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths), as per Lozano et al., 2012.
According to the World Health Organization, about 2 billion people worldwide have been infected with the Hepatitis B Virus and about 360 million live with chronic Hepatitis B infection.
As per European Centre for Disease Prevention and Control (ECDC), the prevalence of HBV in the general population is heterogeneous in Europe ranging 0.1-7 % depending on the country.
The global prevalence of HBV infection varies widely.
HBV infection ranks 15th among all causes of human mortality [Lozano et al., 2012]
For more details visit: https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market